MedTrace Logo

Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

NCT02461888 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2025-12-17

No results posted yet for this study

Summary

This study evaluates a new treatment combination of ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory multiple myeloma. Participants will either receive ixazomib with cyclophosphamide and dexamethasone or cyclophosphamide and dexamethasone alone.

Conditions

Interventions

DRUG

Ixazomib

Chemotherapy

DRUG

Cyclophosphamide

Chemotherapy

DRUG

Dexamethasone

Chemotherapy

Sponsors & Collaborators

  • Myeloma UK

    collaborator OTHER

  • Millennium Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • University of Leeds

    lead OTHER

Principal Investigators

  • Gordon Cook · Leeds Teaching Hospitals NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2022-04-30
Completion
2025-01-19

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02461888 on ClinicalTrials.gov